Javascript must be enabled to continue!
Method Development and Validation of Irbesartan by RP-HPLC
View through CrossRef
A simple, sensitive, rapid and selective isocratic reversed phase High Performance Liquid Chromatographic (HPLC) method has been developed for Irbesartan from bulk drug using a mobile phase consisting mixture of Menthanol: Water (pH 2.8) (80:20v/v) at the flow rate of 1.0 mL/min. A Cosmosil C18 (250cm x 4.6mm, 5μm) column was used as stationary phase. The retention time of Irbesartan found to be 3.30 min. The eluent were detected at 209nm. Linearity was observed in the concentration range of 60-100ppm for Irbesartan. Percent recoveries obtained for Irbesartan were 98.66%. The correlation coefficient for Irbesartan was found to be 0.997. After performing analysis by different analysts, it was found that the RPHPLC method for the determination of Irbesartan was found to be Rugged. Percent RSD for robustness was well within the acceptable USP limits, ensuring that the proposed method was robust. The LOD were 0.074ug/ml Irbesartan. For Irbesartan, the LOQ were found to be 0.24μg/ml. This demonstrated that the developed RP-HPLC method was simple, linear, precise, accurate, robust, and Rugged, could be conveniently adopted for the routine quality control analysis of Irbesartan.
A and V Publications
Title: Method Development and Validation of Irbesartan by RP-HPLC
Description:
A simple, sensitive, rapid and selective isocratic reversed phase High Performance Liquid Chromatographic (HPLC) method has been developed for Irbesartan from bulk drug using a mobile phase consisting mixture of Menthanol: Water (pH 2.
8) (80:20v/v) at the flow rate of 1.
0 mL/min.
A Cosmosil C18 (250cm x 4.
6mm, 5μm) column was used as stationary phase.
The retention time of Irbesartan found to be 3.
30 min.
The eluent were detected at 209nm.
Linearity was observed in the concentration range of 60-100ppm for Irbesartan.
Percent recoveries obtained for Irbesartan were 98.
66%.
The correlation coefficient for Irbesartan was found to be 0.
997.
After performing analysis by different analysts, it was found that the RPHPLC method for the determination of Irbesartan was found to be Rugged.
Percent RSD for robustness was well within the acceptable USP limits, ensuring that the proposed method was robust.
The LOD were 0.
074ug/ml Irbesartan.
For Irbesartan, the LOQ were found to be 0.
24μg/ml.
This demonstrated that the developed RP-HPLC method was simple, linear, precise, accurate, robust, and Rugged, could be conveniently adopted for the routine quality control analysis of Irbesartan.
Related Results
e0188 Enalapril, Irbesartan and Ang-(1-7) prevent atrial tachycardia-induced sodium channel remodelling
e0188 Enalapril, Irbesartan and Ang-(1-7) prevent atrial tachycardia-induced sodium channel remodelling
Purpose
Recent studies indicated that the activation of renin-angiotensin system (RAS) played an important role in the development and recurrence of atrial fibril...
Irbesartan treatment up‐regulates hepatic expression of PPARα and its target genes in obese Koletsky (fak/fak) rats: a link to amelioration of hypertriglyceridaemia
Irbesartan treatment up‐regulates hepatic expression of PPARα and its target genes in obese Koletsky (fak/fak) rats: a link to amelioration of hypertriglyceridaemia
BACKGROUND AND PURPOSEHypertriglyceridaemia is associated with an increased risk of cardiovascular disease. Irbesartan, a well‐established angiotensin II type 1 receptor (AT1) bloc...
Novel Role of Irbesartan in Elevating Serum High Density Lipoprotein in Hypercholesterolemic Animal Model
Novel Role of Irbesartan in Elevating Serum High Density Lipoprotein in Hypercholesterolemic Animal Model
Objective: To explore the HDL cholesterol-raising capacity of Irbesartan (an antihypertensive drug) in rabbit'sserum.Study Design: Laboratory-based experimental study.Place and Dur...
Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model
Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model
To investigate the effect of Irbesartan on the changes of myocardial advanced glycation end products and their receptor (AGEs-RAGE), and matrix metalloproteinases (MMPs) systems in...
Validation in Doctoral Education: Exploring PhD Students’ Perceptions of Belonging to Scaffold Doctoral Identity Work
Validation in Doctoral Education: Exploring PhD Students’ Perceptions of Belonging to Scaffold Doctoral Identity Work
Aim/Purpose: The aim of this article is to make a case of the role of validation in doctoral education. The purpose is to detail findings from three studies which explore PhD stude...
PBPK modeling of irbesartan: incorporation of hepatic uptake
PBPK modeling of irbesartan: incorporation of hepatic uptake
AbstractPhysiological based pharmacokinetic (PBPK) modeling is now commonly used in drug development to integrate human or animal physiological data in order to predict pharmacokin...
EFFECT OF IRBESARTAN ON THE BURDEN OF ATRIAL FIBRILLATION IN THE HYPERTENSIVE PATIENTS WITH BRADYCARDIA-TACHYCARDIA SYNDROME UNDERGOING CARDIAC PACEMAKER IMPLANTATION
EFFECT OF IRBESARTAN ON THE BURDEN OF ATRIAL FIBRILLATION IN THE HYPERTENSIVE PATIENTS WITH BRADYCARDIA-TACHYCARDIA SYNDROME UNDERGOING CARDIAC PACEMAKER IMPLANTATION
Objectives
To evaluate the effect of irbesartan, an angiotensin-receptor blocker, on the prevention of paroxysmal atrial fibrillation in the hypertensive patients...
Role of cardiotrophin-1 in a canine model of atrial fibrillation and the effect of irbesartan on cardiotrophin-1
Role of cardiotrophin-1 in a canine model of atrial fibrillation and the effect of irbesartan on cardiotrophin-1
Objective
Atrial fibrillation (AF) is one of the most common arrhythmias. The atrial interstitial fibrosis, is favourable for the occurrence and persistence of AF...

